Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris
Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris
复制标题
DOI：
10.1186/s12933-014-0145-4
复制
发表时间：
2014-11-01
影响因子：
9.3
通讯作者：
Zhou, Yujie
中科院分区：
文献类型：
--
作者：
Ji, Qingwei;Lin, Yingzhong;Zhou, Yujie
背景资料：近年来的研究表明，循环脂肪因子与急性冠状动脉综合征（ACS）包括不稳定型心绞痛（UAP）和急性心肌梗死（AMI）的发生有关。chemerin作为一种新的脂肪因子，与动脉粥样硬化和冠状动脉疾病的发生有关。方法：采用酶联免疫吸附法（ELISA）测定60例稳定型心绞痛（SAP）、60例不稳定型心绞痛（UAP）、60例急性心肌梗死（AMI）患者和40例正常对照组血浆chemerin和脂联素水平。采用GE ViVid E7型超声仪测量左室舒张末期内径（LVEDD）和左室射血分数（LVEF），并在冠状动脉造影后采用Gensini冠状动脉评分评估患者冠状动脉狭窄程度。ACS患者的血浆chemerin水平显著高于对照组和SAP组，ACS患者血浆脂联素水平显著低于对照组。相关分析显示，血浆chemerin水平与C反应蛋白（CRP）水平呈正相关（r = 0.29，P < 0.01）与LVEDD与LVEF呈负相关（r = 0.27，P < 0.01）血浆脂联素水平与左室射血分数呈正相关（r =-0.45，P < 0.01相关系数r = 0.53，P < 0.01，与CRP（r =-0.33，P < 0.01）、LVEDD（r =-0.30，P < 0.01）呈负相关。虽然SAP患者chemerin、脂联素与BMI或Gensini冠脉评分之间存在显著相关性，但ACS患者chemerin和脂联素与BMI和Gensini冠脉评分均不相关。此外，Chemerin（OR 1.103，95% CI 1.065 ~ 1.142; P = 0.001）和脂联素（OR 0.871，95% CI 0.776 ~ 0.970; P = 0.018）均与ACS的发生独立相关。
Background: Recent evidence demonstrated that the circulating adipokines were associated with the onset of acute coronary syndrome (ACS) including unstable angina pectoris (UAP) and acute myocardial infarction (AMI). As a novel adipokine, chemerin has been related to atherosclerosis and the presence of coronary artery disease. However, the plasma levels of chemerin in patients with ACS have yet to be investigated.Methods: Plasma levels of chemerin and adiponectin were measured by an enzyme-linked immunosorbent assay (ELISA) in 60 patients with stable angina pectoris (SAP), 60 patients with UAP, 60 patients with AMI and 40 control patients. Left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured using a GE ViVid E7 ultrasonography machine, and the severity of coronary stenosis in patients was estimated with a Gensini coronary score following coronary angiography.Results: Plasma chemerin levels were significantly higher in ACS patients than in the control and SAP groups, while plasma adiponectin levels were significantly lower in ACS patients than the control group. A correlation analysis revealed that plasma chemerin levels were positively correlated with the levels of C-reactive protein (CRP) (r = 0.29, P < 0.01) and LVEDD (r = 0.27, P < 0.01) but negatively correlated with LVEF (r = -0.45, P < 0.01) and that plasma adiponectin levels were positively correlated with LVEF (r = 0.53, P < 0.01) but negatively correlated with CRP (r = -0.33, P < 0.01) and LVEDD (r = -0.30, P < 0.01). Although significant correlations between chemerin, adiponectin and BMI or the Gensini coronary score were found in patients with SAP, neither chemerin nor adiponectin was correlated with BMI and the Gensini coronary score in patients with ACS. Furthermore, both chemerin (OR 1.103, 95% CI 1.065 to 1.142; P = 0.001) and adiponectin (OR 0.871, 95% CI 0.776 to 0.970; P = 0.018) were independently associated with the presence of ACS.Conclusions: Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris.